| pubmed-article:10728951 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10728951 | lifeskim:mentions | umls-concept:C0004238 | lld:lifeskim |
| pubmed-article:10728951 | lifeskim:mentions | umls-concept:C0442027 | lld:lifeskim |
| pubmed-article:10728951 | lifeskim:mentions | umls-concept:C0002598 | lld:lifeskim |
| pubmed-article:10728951 | lifeskim:mentions | umls-concept:C0178602 | lld:lifeskim |
| pubmed-article:10728951 | lifeskim:mentions | umls-concept:C0205171 | lld:lifeskim |
| pubmed-article:10728951 | lifeskim:mentions | umls-concept:C1280519 | lld:lifeskim |
| pubmed-article:10728951 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:10728951 | pubmed:dateCreated | 2000-3-31 | lld:pubmed |
| pubmed-article:10728951 | pubmed:abstractText | The efficacy of amiodarone has been proved in long-term maintenance of sinus rhythm (SR) in patients with paroxysmal atrial fibrillation (AF). The present study evaluates the efficacy and safety of a single oral dose of amiodarone in patients with recent-onset AF (<48 hours). Seventy-two patients were randomized to receive 30 mg/kg of either amiodarone or placebo. Conversion to SR was verified by 24-hour Holter monitoring. Ten patients were excluded because of SR in the beginning of monitoring or technical failure during Holter monitoring. The remaining study groups were comparable (n = 31 for each), except that in the placebo group beta blockers were more common. The patients receiving amiodarone converted to SR more effectively than those receiving placebo (p<0.0001). At 8 hours, approximately 50% of patients in the amiodarone group and 20% in the placebo group (Holter successful) had converted to SR, whereas after 24 hours the corresponding figures were 87% and 35%, respectively. The median time for conversion (8.7 hours for amiodarone and 7.9 hours for placebo) did not differ in the groups. Amiodarone was hemodynamically well tolerated, and the number of adverse events in the study groups was similar. Amiodarone as a single oral dose of 30 mg/kg appears to be effective and safe in patients with recent-onset AF. | lld:pubmed |
| pubmed-article:10728951 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10728951 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10728951 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10728951 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:10728951 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10728951 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10728951 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10728951 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:10728951 | pubmed:issn | 0002-9149 | lld:pubmed |
| pubmed-article:10728951 | pubmed:author | pubmed-author:LiljaMM | lld:pubmed |
| pubmed-article:10728951 | pubmed:author | pubmed-author:LinnaluotoMM | lld:pubmed |
| pubmed-article:10728951 | pubmed:author | pubmed-author:NiemeläMM | lld:pubmed |
| pubmed-article:10728951 | pubmed:author | pubmed-author:PeuhkurinenKK | lld:pubmed |
| pubmed-article:10728951 | pubmed:author | pubmed-author:JuvonenJJ | lld:pubmed |
| pubmed-article:10728951 | pubmed:author | pubmed-author:YlitaloAA | lld:pubmed |
| pubmed-article:10728951 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10728951 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:10728951 | pubmed:volume | 85 | lld:pubmed |
| pubmed-article:10728951 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10728951 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10728951 | pubmed:pagination | 462-5 | lld:pubmed |
| pubmed-article:10728951 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:10728951 | pubmed:meshHeading | pubmed-meshheading:10728951... | lld:pubmed |
| pubmed-article:10728951 | pubmed:meshHeading | pubmed-meshheading:10728951... | lld:pubmed |
| pubmed-article:10728951 | pubmed:meshHeading | pubmed-meshheading:10728951... | lld:pubmed |
| pubmed-article:10728951 | pubmed:meshHeading | pubmed-meshheading:10728951... | lld:pubmed |
| pubmed-article:10728951 | pubmed:meshHeading | pubmed-meshheading:10728951... | lld:pubmed |
| pubmed-article:10728951 | pubmed:meshHeading | pubmed-meshheading:10728951... | lld:pubmed |
| pubmed-article:10728951 | pubmed:meshHeading | pubmed-meshheading:10728951... | lld:pubmed |
| pubmed-article:10728951 | pubmed:meshHeading | pubmed-meshheading:10728951... | lld:pubmed |
| pubmed-article:10728951 | pubmed:meshHeading | pubmed-meshheading:10728951... | lld:pubmed |
| pubmed-article:10728951 | pubmed:meshHeading | pubmed-meshheading:10728951... | lld:pubmed |
| pubmed-article:10728951 | pubmed:meshHeading | pubmed-meshheading:10728951... | lld:pubmed |
| pubmed-article:10728951 | pubmed:meshHeading | pubmed-meshheading:10728951... | lld:pubmed |
| pubmed-article:10728951 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:10728951 | pubmed:articleTitle | Effectiveness of amiodarone as a single oral dose for recent-onset atrial fibrillation. | lld:pubmed |
| pubmed-article:10728951 | pubmed:affiliation | Department of Internal Medicine, Kuopio University Hospital, Finland. Keijo.Peuhkurinen@kuh.fi | lld:pubmed |
| pubmed-article:10728951 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10728951 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:10728951 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:10728951 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:10728951 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10728951 | lld:pubmed |
